CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 217 enrolled
Drug / intervention
Etanercept via Autoinjector A +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01875991
NCT01875991Phase 4Completed
CompareCT.gov

An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept

Amgen·interventional·Posted Jun 12, 2013·Updated Sep 4, 2018

In Brief

A Phase 4 clinical trial evaluating Etanercept via Autoinjector A and Etanercept via Autoinjector B for Rheumatoid Arthritis and Plaque Psoriasis. Completed, enrolled 217 participants across 37 sites in 2 countries.

Detailed Summary

The study will estimate the preference of rheumatoid arthritis (RA) and Plaque Psoriasis (PsO) patients who self inject etanercept for one of two experimental autoinjectors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis, Plaque Psoriasis
CountriesCanada, United States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 12, 2013
Enrollment StartJun 5, 2013
Primary CompletionMar 4, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 13.1 years ago

Interventions

Etanercept via Autoinjector Adrug

Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.

Etanercept via Autoinjector Bdrug

Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.